# Melanotan I (Afamelanotide): Evidence, Mechanism & Legal Status

> A clinical monograph on Melanotan I — INN afamelanotide, marketed as SCENESSE — the only FDA-approved melanocortin agonist, with Grade-A EPP photoprotection data and a separate unapproved gray-market tanning identity.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Melanotan I — INN **afamelanotide**, marketed as **SCENESSE** — is the rare gray-market-famous peptide that actually earned its FDA approval, but for one narrow, well-studied use: photoprotection in **erythropoietic protoporphyria (EPP)**, graded **A** on two placebo-controlled phase 3 RCTs. The injected peptide sold online for cosmetic tanning is the same molecule but **unapproved, unregulated, and unproven for tanning**, and it is prohibited for athletes under WADA Section S2.[2](https://peptidevox.com/#r2)[5](https://peptidevox.com/#r5)[16](https://peptidevox.com/#r16)

Melanotan I (afamelanotide; CUV1647; CAS 75921-69-6) is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that drives photoprotective pigmentation. It is best known online as a self-injected tanning peptide, yet it is also the **only melanocortin agonist with FDA approval for any indication**.[1](https://peptidevox.com/#r1)[7](https://peptidevox.com/#r7) Those two identities — a legitimate orphan drug and an unregulated 'research chemical' — are the heart of this monograph, and they must not be conflated.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. The FDA-approved SCENESSE implant is administered only by trained clinicians; the injected gray-market 'melanotan-1' is an unapproved product of unknown purity. Doses and routes are reported strictly as they appear in the FDA label and published trials, for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is Melanotan I and how does it work?

Afamelanotide is a synthetic linear tridecapeptide analogue of human alpha-MSH, structurally **[Nle4-D-Phe7]-alpha-MSH**: methionine at position 4 is replaced by norleucine and L-phenylalanine at position 7 by D-phenylalanine.[13](https://peptidevox.com/#r13)[1](https://peptidevox.com/#r1) Those two substitutions confer resistance to proteolytic degradation and substantially greater potency and duration of action than native alpha-MSH.[10](https://peptidevox.com/#r10)

Like all melanocortins it can engage the MC1-MC5 receptor family, but at therapeutic exposure afamelanotide is **functionally MC1R-predominant**, with minimal MC3R/MC4R/MC5R activity. This distinguishes it from the non-selective tanning peptide Melanotan II, which activates MC4R and produces erections, nausea and autonomic effects.[21](https://peptidevox.com/#r21)[1](https://peptidevox.com/#r1) The mechanism is well characterized: afamelanotide binds MC1R on epidermal melanocytes, activates adenylyl cyclase, raises intracellular cAMP, and engages the MITF transcription pathway, which upregulates **tyrosinase** — the rate-limiting enzyme of melanogenesis — shifting synthesis toward **eumelanin**, the photoprotective brown-black pigment.[1](https://peptidevox.com/#r1)[21](https://peptidevox.com/#r21) The increased epidermal eumelanin absorbs, scatters and quenches the visible and UV light that, in EPP, photo-activates accumulated protoporphyrin IX and triggers phototoxic pain.[1](https://peptidevox.com/#r1) MC1R signaling also has melanin-independent antioxidant and anti-inflammatory effects and is reported to stimulate DNA repair.[2](https://peptidevox.com/#r2) A newer mechanistic finding is that UV and alpha-MSH drive MC1R into primary cilia via the BBSome, sustaining cAMP signaling and Sox9-mediated upregulation of melanogenesis genes.[12](https://peptidevox.com/#r12)

On pharmacokinetics: the approved product is a controlled-release bioresorbable subcutaneous implant; pigmentation appears within roughly two days and the implant releases drug over about two months, which supports the every-60-day regimen.[5](https://peptidevox.com/#r5)[11](https://peptidevox.com/#r11) Free peptide is rapidly hydrolyzed to component amino acids, and afamelanotide is not a cytochrome P450 substrate; the FDA label does not state a discrete plasma half-life, so secondary 'half-life' figures should be treated as approximate.[1](https://peptidevox.com/#r1)[10](https://peptidevox.com/#r10)

## What is the evidence by indication?

The evidence is sharply tiered: robust for EPP, suggestive for vitiligo, and essentially absent for the tanning use that drives the online market.

  Melanotan I (afamelanotide) evidence by indication

    IndicationBest evidenceGrade

    Erythropoietic protoporphyria (photoprotection)Two placebo-controlled phase 3 RCTs (pooled n=168) + large post-authorization cohorts; FDA/EMA-approvedA
    Vitiligo (add-on to NB-UVB)Small randomized trials showing greater, faster repigmentation, esp. in darker skin; not approvedB
    Other dermatology (solar urticaria, PLE, xeroderma pigmentosum)Case series / early-phase, mostly unpublished or hypothesis-generatingC-to-D
    Cosmetic tanningNo efficacy or safety RCTs; off-label gray-market use only; no regulatory approval anywhereD

The pivotal EPP evidence is two multicenter, randomized, double-blind, placebo-controlled phase 3 trials of the 16 mg implant versus placebo, pooled in Langendonk et al., *NEJM* 2015 (total enrolled n=168).[2](https://peptidevox.com/#r2) In the US trial (6 months, 3 implants), median pain-free direct-sunlight time was 69.4 hours on afamelanotide versus 40.8 hours on placebo (P=0.04); in the EU trial (9 months, 5 implants), median pain-free time was 6.0 hours versus 0.8 hours (P=0.005), with fewer phototoxic reactions (77 vs 146; P=0.04) and significantly improved quality of life.[2](https://peptidevox.com/#r2) This underpinned EMA approval in 2014-2015 and FDA approval in 2019, and it is reinforced by large post-authorization cohorts: a German PASS study of 200 EPP patients reported EPP-QoL gains averaging roughly 100% with 91% treatment continuation and a safety profile consistent with the trials.[9](https://peptidevox.com/#r9) The pivotal phase 3 results are catalogued on PubMed at [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25230094/) for the vitiligo program and across the NEJM record for EPP, and readers can verify the prescribing details directly in the FDA label.[4](https://peptidevox.com/#r4)

For vitiligo, a randomized multicenter trial (Lim et al., *JAMA Dermatology* 2015) added monthly 16 mg afamelanotide to narrowband UV-B and produced greater repigmentation (48.6% vs 33.3%) and faster onset, with benefit concentrated in darker skin types — but the trials are small and afamelanotide is **not FDA-approved for vitiligo** as of 2026.[3](https://peptidevox.com/#r3)[15](https://peptidevox.com/#r15) For cosmetic tanning, despite being the very molecule sold online for that purpose, there are **no phase 3 efficacy or safety trials**, and no regulator approves it for tanning.[20](https://peptidevox.com/#r20)[21](https://peptidevox.com/#r21)

Proven vs hyped
Proven (Grade A): EPP photoprotection with the approved implant. Promising but not approved (Grade B): vitiligo as an NB-UVB add-on. Hyped and unproven (Grade D): cosmetic tanning — no efficacy RCTs, no approval, and sourced from unregulated products. The clean line: the approved EPP implant is legitimate medicine; the injected tanning peptide is not.[5](https://peptidevox.com/#r5)[18](https://peptidevox.com/#r18)

## What doses appear in the literature?

Reported strictly as information, not a protocol. The **approved EPP regimen** is one 16 mg afamelanotide bioresorbable implant — a sterile white-to-off-white rod about 1.7 cm long — inserted subcutaneously above the anterior supra-iliac crest every 2 months by a healthcare professional trained in the implantation procedure.[5](https://peptidevox.com/#r5)[7](https://peptidevox.com/#r7) In the pivotal trials, the US phase 3 used 3 implants over 6 months and the EU phase 3 used 5 implants over 9 months; the vitiligo RCT used monthly 16 mg implants for 4 months alongside NB-UVB.[2](https://peptidevox.com/#r2)[3](https://peptidevox.com/#r3) The implant requires **no reconstitution** — it is a solid, pre-formed bioresorbable rod, not a reconstituted injectable. The gray-market 'melanotan-1' tanning product is, by contrast, a lyophilized powder reconstituted and self-injected outside the approved route, with no quality assurance and no validated tanning dose.[20](https://peptidevox.com/#r20)

## How safe is Melanotan I?

For the approved implant, the common adverse reactions on the FDA label (incidence over 2%) include implant-site reaction, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus and skin irritation; in pooled trials, implant-site reactions ran about 21% versus 10% on placebo, and events were predominantly mild-to-moderate and transient.[5](https://peptidevox.com/#r5)[1](https://peptidevox.com/#r1) Because afamelanotide darkens pre-existing nevi and freckles, the label requires a **full-body skin examination twice yearly** to monitor for new or changing pigmented lesions.[5](https://peptidevox.com/#r5) Reassuringly, in the German PASS cohort, 30.5% reported pigmentary expressions and the biopsies performed were **all histologically benign**, with no drug-attributed malignancies; the trials reported one melanoma — in the placebo arm.[9](https://peptidevox.com/#r9)[2](https://peptidevox.com/#r2)

The important distinction is that the alarming melanoma and eruptive-nevi case reports in the lay and case literature predominantly involve the non-selective gray-market **Melanotan II**, not regulated afamelanotide — but the theoretical concern of a melanocyte-proliferative stimulus is exactly why the label mandates dermatologic surveillance for any melanocortin tanning agent.[18](https://peptidevox.com/#r18)[1](https://peptidevox.com/#r1) Rare postmarketing hypersensitivity reactions including anaphylaxis have been reported; LiverTox rates hepatotoxicity likelihood as low.[5](https://peptidevox.com/#r5)[1](https://peptidevox.com/#r1) The only contraindication is a history of severe hypersensitivity to afamelanotide or its excipients, and there are no human pregnancy data.[5](https://peptidevox.com/#r5) Crucially, none of the favorable safety data from the regulated implant transfer to the gray-market injected product, which carries contamination, sterility and dosing-accuracy hazards absent from the approved route.[19](https://peptidevox.com/#r19)[20](https://peptidevox.com/#r20)

## What is the FDA and WADA status in 2026?

The FDA approved afamelanotide on **October 8, 2019** as SCENESSE — a first-in-class MC1R agonist implant — to increase pain-free light exposure in adults with EPP, with Orphan Drug and Priority Review designations; the prescribing information was most recently revised in August 2024.[7](https://peptidevox.com/#r7)[5](https://peptidevox.com/#r5) The EMA approved it for EPP in 2014-2015 (with an earlier Italian AIFA approval in 2010).[14](https://peptidevox.com/#r14) There is **no approved indication for cosmetic tanning or vitiligo**, and the injectable 'melanotan-1' sold online for tanning is an unapproved new drug — the same molecule but not the FDA-approved product, typically labeled 'not for human use,' against which the FDA has historically pursued enforcement.[20](https://peptidevox.com/#r20)[23](https://peptidevox.com/#r23) Melanotan peptides are not scheduled controlled substances; the legal issue is unapproved-drug marketing, not the Controlled Substances Act.[22](https://peptidevox.com/#r22)

For athletes the picture is unambiguous: non-approved peptide-hormone analogues fall under **WADA Section S2** (peptide hormones, growth factors, related substances and mimetics), prohibited in and out of competition, and afamelanotide's narrow EPP approval does not create a doping exemption.[16](https://peptidevox.com/#r16)[17](https://peptidevox.com/#r17) Any WADA-tested athlete should treat melanotan as prohibited regardless of cosmetic intent.

**Bottom line.** Afamelanotide is the rare gray-market-famous peptide that genuinely earned its approval — for one narrow, well-studied indication. In adults with EPP, the 16 mg every-2-month implant meaningfully increases pain-free sunlight tolerance on Grade-A RCT evidence with a benign monitored safety profile. Vitiligo (Grade B) is promising but unapproved. Cosmetic tanning — the use that drives the online market — has no efficacy or safety RCTs, no approval, and is sourced from unregulated products of unknown purity. The clear line to hold: the approved EPP implant is legitimate, clinician-administered medicine; the injected tanning peptide is an unapproved, unstudied, unregulated product. Regulatory facts are current as of June 2026 and should be re-verified for any later label or list changes.

---
Source: https://peptidevox.com/peptide-encyclopedia/melanotan-1
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt